<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Coadministration of MPOE with CCl
 <sub xmlns="http://www.w3.org/1999/xhtml">4</sub> significantly improved the liver histopathology (
 <xref ref-type="fig" rid="fig2" class="xref">Figure 2</xref>) and reduced the fibrotic changes (
 <xref ref-type="fig" rid="fig3" class="xref">Figure 3</xref>, 
 <xref ref-type="table" rid="tab5" class="xref">Table 5</xref>). Furthermore, the MPOE-treated group showed a marked reduction in both 
 <italic class="italic">Î±</italic>-SMA- and desmin-immunopositive cells (Figures 
 <xref ref-type="fig" rid="fig4" class="xref">4(c)</xref> and 
 <xref ref-type="fig" rid="fig5" class="xref">5(c)</xref>). These data reflect the efficacy of MPOE to reduce the hepatocellular toxic effects of CCl
 <sub xmlns="http://www.w3.org/1999/xhtml">4</sub> and to suppress HSCs activation and proliferation as well.
</p>
